Article written Tyler Durden
JNJ (Johnson & Johnson) announced Wednesday morning that it would become the 4th U.S. Vaccine to enter Phase 3 trials.
The next step of JNJ will be dosing the first half of the 60,000 volunteers it needs for the trial. Similarly to other vaccine trials, participants are sorted into two groups: one that receives the vaccine, the other that receives a placebo.
JNJ expects the trial to yield results as soon as year-end, allowing the company so seek emergency authorization by the FDA for early next year, should the vaccine prove effective.
If all goes as anticipated, the U.S. plans to vaccinate the most vulnerable patients by the end of the year (i.e. assisted living population), then onto front-line health care workers in January, and then to the rest of the U.S. population soon after.
The U.S. passed 200,000 confirmed COVID-19 deaths Wednesday, while the CDC released holiday guidelines, recommending to avoid an indoor Thanksgiving feast in November, while Halloween trick or treating can continue.
Outside the U.S., China has a handful of projects in Phase 3, while Russia’s Gameleya Institute vaccine recently entered Phase 3 as well. In Australia, the Murdoch Children’s Research Institute is also developing a vaccine.
Works Cited: